49
Participants
Start Date
August 1, 2022
Primary Completion Date
August 31, 2024
Study Completion Date
December 31, 2026
Ensartinib
Participants will receive Ensartinib 225 mg oral once daily from baseline until disease progression, unacceptable toxicity, withdrawal of consent or death.
Bevacizumab
Participants will receive 7.5 mg/kg intravenous on Day 1 of 21 day cycles (every 3 weeks) from baseline until disease progression, unacceptable toxicity, withdrawal of consent or death.
Sun Yat-Sen University Cancer Center, Guangzhou
First Affiliated Hospital of Wenzhou Medical University
OTHER
Second Affiliated Hospital, School of Medicine, Zhejiang University
OTHER
Shenyang Chest Hospital
OTHER
Hebei Medical University Fourth Hospital
OTHER
First People's Hospital of Foshan
OTHER
Fifth Affiliated Hospital, Sun Yat-Sen University
OTHER
Guangzhou Institute of Respiratory Disease
OTHER
Central People's Hospital of Zhanjiang
OTHER
Guangdong Provincial Agricultural Reclamation Central Hospital
UNKNOWN
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
OTHER
West China Hospital
OTHER
The First Affiliated Hospital with Nanjing Medical University
OTHER
Yuebei People's Hospital
OTHER
Yunnan Cancer Hospital
OTHER
Sun Yat-sen University
OTHER